NCT01114230 (Clinical Trial / AGS-16M8F)

Study Title
A First in Man Study to Determine the Safety at Various Dose Levels of AGS-16M8F in Advanced Kidney Cancer (NCT01114230)

Trial Description
The purpose of this dose escalation study is to examine the safety and pharmacokinetics (PK) of AGS-16M8F (also known as AGS 16C3F) administered in subjects with advanced renal cell carcinoma.

The trial is sponsored by Agensys/Astellas Pharma Inc.

Study Data

  • Condition: Advanced Kidney Cancer
  • Interventions:
    • Drugs used in this trial
      • AGS-16M8F
  • Phase: I
  • Enrollment: 26
  • Start: August 2010
  • Completion: November 2012
  • Last Verified: December 2012

Study Schematic 

CT01114230

Return to drup map

Last Editorial review: August 28, 2017
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.